With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.31886-58-5,(R)-(+)-N,N-Dimethyl-1-ferrocenylethylamine,as a common compound, the synthetic route is as follows.
(S)-Ugi-amine 1 (2.57 g, 10 mmol) was dissolved in 25 mL of diethyl ether, and n-butyllithium (8 mL, 2.5 mol/L) was added dropwise to the reaction system under nitrogen protection and ice salt bath cooling. After that, the temperature was slowly raised to room temperature, and the reaction was stirred for 3 hours. To the ice salt bath, chlorobis(3,5-di-t-butylphenyl)phosphine (8.90 g, 20 mmol) was added dropwise thereto, and after the completion of the dropwise addition, the mixture was slowly warmed to room temperature, and the reaction was stirred for 24 hours. The reaction was quenched with saturated sodium bicarbonate solution and extracted with dichloromethane. Dry over anhydrous sodium sulfate, Concentration and column chromatography gave product 7 (3.79 g, 57%).
31886-58-5 (R)-(+)-N,N-Dimethyl-1-ferrocenylethylamine 16212257, achiral-nitrogen-ligands compound, is more and more widely used in various.
Reference£º
Patent; Zhejiang University of Technology; Zhong Weihui; Ling Fei; Nian Sanfei; (14 pag.)CN108774271; (2018); A;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis